Gastrointestinal cancer cells treatment with bevacizumab activates a VEGF autoregulatory mechanism involving telomerase catalytic subunit hTERT via PI3K-AKT, HIF-1α and VEGF receptors

BACKGROUND: Targeting angiogenesis has been considered a promising treatment of choice for a large number of malignancies, including gastrointestinal cancers. Bevacizumab is an anti-vascular endothelial growth factor (anti-VEGF) being used for this purpose. However, treatment efficacy is largely que...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :PLoS One
Главные авторы: Mahfouz, Nadine, Tahtouh, Roula, Alaaeddine, Nada, El Hajj, Joelle, Sarkis, Riad, Hachem, Ray, Raad, Issam, Hilal, George
Формат: Artigo
Язык:Inglês
Опубликовано: Public Library of Science 2017
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5466359/
https://ncbi.nlm.nih.gov/pubmed/28594907
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0179202
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы